Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial
Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade with afatinib plus paclitaxel has superior outcomes versus swit...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2016-03, Vol.27 (3), p.417-423 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 423 |
|---|---|
| container_issue | 3 |
| container_start_page | 417 |
| container_title | Annals of oncology |
| container_volume | 27 |
| creator | Yang, J.C.-H. Park, K. Kim, J.-H. Chen, Y.-M. Chouaid, C. Feng, J.-F. Lu, S. Vinnyk, Y. Wiewrodt, R. Zhou, C. Wang, B. Planchard, D. Ignatius Ou, SaiHong Planchard, David Schuler, Martin Chand, Vikram Rohr, Klaus Martin, Claudio Marcelo Zarba, Juan Jose Richardet, Martín Mainwaring, Paul Greil, Richard Humblet, Yves Bustin, Frédérique Galdermans, Danny Lambrechts, Marc Vercauter, Piet Wang, Jin Huang, Cheng Wu, Yilong Cheng, Ying Qin, Shukui Zhang, Yiping Lu, Shun Garicochea, Bernardo Alanko, Tuomo Cadranel, Jacques Chouaid, Christos Zalcman, Gérard Perol, Maurice Fournel, Pierre Gervais, Radj Rotarski, Maciej Thomas, Michael Keilholz, Ulrich Laack, Eckart Strausz, Janos Sarosi, Veronika Jain, Minish Venkatesan, Srinivasan Sharma, Lalit Dadhich, Hemant Nagarkar, Rajnish Vasant Gottfried, Maya Stemmer, Solomon Migliorino, Maria Rita Grossi, Francesco Gridelli, Cesare Milandri, Carlo Platania, Marco Delgado, Francisco Gutierrez Baca, Othon Padilla Dingemans, A.M.C. Herder, G.J.M. Gans, S.J.M. Salas Sánchez, Jorge Fernando Pantigoso, Wilbert Rodriguez Palomino, Osbert Luis Mejia Kazarnowicz, Andrzej Jassem, Jacek Lubennikov, Vladimir Karaseva, Nina Ragulin, Yuri Garrido, Pilar González Larriba, José Luis Camps, Carlos Campelo, Rosario García Cobo, Manuel Felip, Enriqueta Kim, Dong-Wan Kim, Joo-Hang Han, Ji-Youn Kim, Young-Chul Yang, Chih-Hsin Hsia, Te-Chun Tsai, Ying-Huang Tsao, Thomas Chang-Yao Ho, Ching-Liang Vinnyk, Yuriy Popovych, Oleksandr Ponomarova, Olga Bondarenko, Igor Shah, Riyaz Spicer, James Brown, Emma Upadhyay, Sunil Summers, Yvonne Gurtler, Jayne Meza, Luis Thropay, John |
| description | Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade with afatinib plus paclitaxel has superior outcomes versus switching to chemotherapy alone in patients acquiring resistance to erlotinib/gefitinib and afatinib monotherapy.
Patients with relapsed/refractory disease following ≥1 line of chemotherapy, and whose tumors had progressed following initial disease control (≥12 weeks) with erlotinib/gefitinib and thereafter afatinib (50 mg/day), were randomized 2:1 to receive afatinib plus paclitaxel (40 mg/day; 80 mg/m2/week) or investigator's choice of single-agent chemotherapy. The primary end point was progression-free survival (PFS). Other end points included objective response rate (ORR), overall survival (OS), safety and patient-reported outcomes.
Two hundred and two patients with progressive disease following clinical benefit from afatinib were randomized to afatinib plus paclitaxel (n = 134) or single-agent chemotherapy (n = 68). PFS (median 5.6 versus 2.8 months, hazard ratio 0.60, P = 0.003) and ORR (32.1% versus 13.2%, P = 0.005) significantly improved with afatinib plus paclitaxel. There was no difference in OS. Global health status/quality of life was maintained with afatinib plus paclitaxel over the entire treatment period. The median treatment duration was 133 and 51 days with afatinib plus paclitaxel and single-agent chemotherapy, respectively; 48.5% of patients receiving afatinib plus paclitaxel and 30.0% of patients receiving single-agent chemotherapy experienced drug-related grade 3/4 adverse events. Treatment-related adverse events were consistent with those previously reported with each agent.
Afatinib plus paclitaxel improved PFS and ORR compared with single-agent chemotherapy in patients who acquired resistance to erlotinib/gefitinib and progressed on afatinib after initial benefit. LUX-Lung 5 is the first prospective trial to demonstrate the benefit of continued ErbB targeting post-progression, versus switching to single-agent chemotherapy.
NCT01085136 (clinicaltrials.gov). |
| doi_str_mv | 10.1093/annonc/mdv597 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4769992</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753419355942</els_id><sourcerecordid>S0923753419355942</sourcerecordid><originalsourceid>FETCH-LOGICAL-c435t-1ac65ec5f9689f0d0c3ce61e67bad0b5fb36cfcd120b30519fc16218aba10c693</originalsourceid><addsrcrecordid>eNp1kcFu1DAURS0EosPAki3yBxDGTmJnzAKpqiiMNBIbKrGzHPt5YuTYkZ1ONf0hfrMeUipYsHrSu9f36Pki9JaSD5SIZqNCiEFvRnNkonuGVpRxUW1JS5-jFRF1U3WsaS_Qq5x_EkK4qMVLdFFz3vKOiRX6dWnV7ILrcQ-nGAyeUjwkyNnFgF3AU1EhzBnfuXnABVXlUXlfafAe-9twwFoFDQnb6H28c-fFAGOcB0hqOr3HkHz8DdgcwLoFpQpHPXI_4mlQGfBut8OpCHF092Dw_uZHtT_HMzwnp_xr9MIqn-HN41yjm-vP36--VvtvX3ZXl_tKtw2bK6o0Z6CZFXwrLDFENxo4Bd71ypCe2b7h2mpDa9I3hFFhNeU13apeUaK5aNbo05I73fYjGF1uT8rLKblRpZOMysl_leAGeYhH2XZciPLfa1QtATrFnBPYp7eUyHNjcmlMLo0V_7u_gU_uPxUVQ7cYoJx9dJBk1qUSDcYl0LM00f0n-gGOlK4b</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Yang, J.C.-H. ; Park, K. ; Kim, J.-H. ; Chen, Y.-M. ; Chouaid, C. ; Feng, J.-F. ; Lu, S. ; Vinnyk, Y. ; Wiewrodt, R. ; Zhou, C. ; Wang, B. ; Planchard, D. ; Ignatius Ou, SaiHong ; Planchard, David ; Schuler, Martin ; Chand, Vikram ; Rohr, Klaus ; Martin, Claudio Marcelo ; Zarba, Juan Jose ; Richardet, Martín ; Mainwaring, Paul ; Greil, Richard ; Humblet, Yves ; Bustin, Frédérique ; Galdermans, Danny ; Lambrechts, Marc ; Vercauter, Piet ; Wang, Jin ; Huang, Cheng ; Wu, Yilong ; Cheng, Ying ; Qin, Shukui ; Zhang, Yiping ; Lu, Shun ; Garicochea, Bernardo ; Alanko, Tuomo ; Cadranel, Jacques ; Chouaid, Christos ; Zalcman, Gérard ; Perol, Maurice ; Fournel, Pierre ; Gervais, Radj ; Rotarski, Maciej ; Thomas, Michael ; Keilholz, Ulrich ; Laack, Eckart ; Strausz, Janos ; Sarosi, Veronika ; Jain, Minish ; Venkatesan, Srinivasan ; Sharma, Lalit ; Dadhich, Hemant ; Nagarkar, Rajnish Vasant ; Gottfried, Maya ; Stemmer, Solomon ; Migliorino, Maria Rita ; Grossi, Francesco ; Gridelli, Cesare ; Milandri, Carlo ; Platania, Marco ; Delgado, Francisco Gutierrez ; Baca, Othon Padilla ; Dingemans, A.M.C. ; Herder, G.J.M. ; Gans, S.J.M. ; Salas Sánchez, Jorge Fernando ; Pantigoso, Wilbert Rodriguez ; Palomino, Osbert Luis Mejia ; Kazarnowicz, Andrzej ; Jassem, Jacek ; Lubennikov, Vladimir ; Karaseva, Nina ; Ragulin, Yuri ; Garrido, Pilar ; González Larriba, José Luis ; Camps, Carlos ; Campelo, Rosario García ; Cobo, Manuel ; Felip, Enriqueta ; Kim, Dong-Wan ; Kim, Joo-Hang ; Han, Ji-Youn ; Kim, Young-Chul ; Yang, Chih-Hsin ; Hsia, Te-Chun ; Tsai, Ying-Huang ; Tsao, Thomas Chang-Yao ; Ho, Ching-Liang ; Vinnyk, Yuriy ; Popovych, Oleksandr ; Ponomarova, Olga ; Bondarenko, Igor ; Shah, Riyaz ; Spicer, James ; Brown, Emma ; Upadhyay, Sunil ; Summers, Yvonne ; Gurtler, Jayne ; Meza, Luis ; Thropay, John</creator><creatorcontrib>Yang, J.C.-H. ; Park, K. ; Kim, J.-H. ; Chen, Y.-M. ; Chouaid, C. ; Feng, J.-F. ; Lu, S. ; Vinnyk, Y. ; Wiewrodt, R. ; Zhou, C. ; Wang, B. ; Planchard, D. ; Ignatius Ou, SaiHong ; Planchard, David ; Schuler, Martin ; Chand, Vikram ; Rohr, Klaus ; Martin, Claudio Marcelo ; Zarba, Juan Jose ; Richardet, Martín ; Mainwaring, Paul ; Greil, Richard ; Humblet, Yves ; Bustin, Frédérique ; Galdermans, Danny ; Lambrechts, Marc ; Vercauter, Piet ; Wang, Jin ; Huang, Cheng ; Wu, Yilong ; Cheng, Ying ; Qin, Shukui ; Zhang, Yiping ; Lu, Shun ; Garicochea, Bernardo ; Alanko, Tuomo ; Cadranel, Jacques ; Chouaid, Christos ; Zalcman, Gérard ; Perol, Maurice ; Fournel, Pierre ; Gervais, Radj ; Rotarski, Maciej ; Thomas, Michael ; Keilholz, Ulrich ; Laack, Eckart ; Strausz, Janos ; Sarosi, Veronika ; Jain, Minish ; Venkatesan, Srinivasan ; Sharma, Lalit ; Dadhich, Hemant ; Nagarkar, Rajnish Vasant ; Gottfried, Maya ; Stemmer, Solomon ; Migliorino, Maria Rita ; Grossi, Francesco ; Gridelli, Cesare ; Milandri, Carlo ; Platania, Marco ; Delgado, Francisco Gutierrez ; Baca, Othon Padilla ; Dingemans, A.M.C. ; Herder, G.J.M. ; Gans, S.J.M. ; Salas Sánchez, Jorge Fernando ; Pantigoso, Wilbert Rodriguez ; Palomino, Osbert Luis Mejia ; Kazarnowicz, Andrzej ; Jassem, Jacek ; Lubennikov, Vladimir ; Karaseva, Nina ; Ragulin, Yuri ; Garrido, Pilar ; González Larriba, José Luis ; Camps, Carlos ; Campelo, Rosario García ; Cobo, Manuel ; Felip, Enriqueta ; Kim, Dong-Wan ; Kim, Joo-Hang ; Han, Ji-Youn ; Kim, Young-Chul ; Yang, Chih-Hsin ; Hsia, Te-Chun ; Tsai, Ying-Huang ; Tsao, Thomas Chang-Yao ; Ho, Ching-Liang ; Vinnyk, Yuriy ; Popovych, Oleksandr ; Ponomarova, Olga ; Bondarenko, Igor ; Shah, Riyaz ; Spicer, James ; Brown, Emma ; Upadhyay, Sunil ; Summers, Yvonne ; Gurtler, Jayne ; Meza, Luis ; Thropay, John ; for the LUX-Lung 5 Investigators ; LUX-Lung 5 Investigators</creatorcontrib><description>Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade with afatinib plus paclitaxel has superior outcomes versus switching to chemotherapy alone in patients acquiring resistance to erlotinib/gefitinib and afatinib monotherapy.
Patients with relapsed/refractory disease following ≥1 line of chemotherapy, and whose tumors had progressed following initial disease control (≥12 weeks) with erlotinib/gefitinib and thereafter afatinib (50 mg/day), were randomized 2:1 to receive afatinib plus paclitaxel (40 mg/day; 80 mg/m2/week) or investigator's choice of single-agent chemotherapy. The primary end point was progression-free survival (PFS). Other end points included objective response rate (ORR), overall survival (OS), safety and patient-reported outcomes.
Two hundred and two patients with progressive disease following clinical benefit from afatinib were randomized to afatinib plus paclitaxel (n = 134) or single-agent chemotherapy (n = 68). PFS (median 5.6 versus 2.8 months, hazard ratio 0.60, P = 0.003) and ORR (32.1% versus 13.2%, P = 0.005) significantly improved with afatinib plus paclitaxel. There was no difference in OS. Global health status/quality of life was maintained with afatinib plus paclitaxel over the entire treatment period. The median treatment duration was 133 and 51 days with afatinib plus paclitaxel and single-agent chemotherapy, respectively; 48.5% of patients receiving afatinib plus paclitaxel and 30.0% of patients receiving single-agent chemotherapy experienced drug-related grade 3/4 adverse events. Treatment-related adverse events were consistent with those previously reported with each agent.
Afatinib plus paclitaxel improved PFS and ORR compared with single-agent chemotherapy in patients who acquired resistance to erlotinib/gefitinib and progressed on afatinib after initial benefit. LUX-Lung 5 is the first prospective trial to demonstrate the benefit of continued ErbB targeting post-progression, versus switching to single-agent chemotherapy.
NCT01085136 (clinicaltrials.gov).</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdv597</identifier><identifier>PMID: 26646759</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Afatinib ; Antineoplastic Agents - therapeutic use ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Disease Progression ; Disease-Free Survival ; ErbB Receptors - antagonists & inhibitors ; ErbB Receptors - genetics ; Erlotinib Hydrochloride - therapeutic use ; Female ; Gefitinib ; Humans ; Lung Neoplasms - drug therapy ; Male ; Middle Aged ; NSCLC ; Original ; paclitaxel ; Paclitaxel - adverse effects ; Paclitaxel - therapeutic use ; Prospective Studies ; Protein Kinase Inhibitors - therapeutic use ; Quinazolines - adverse effects ; Quinazolines - therapeutic use ; squamous cell</subject><ispartof>Annals of oncology, 2016-03, Vol.27 (3), p.417-423</ispartof><rights>2016 THE AUTHORS</rights><rights>The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology.</rights><rights>The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. 2015</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c435t-1ac65ec5f9689f0d0c3ce61e67bad0b5fb36cfcd120b30519fc16218aba10c693</citedby><cites>FETCH-LOGICAL-c435t-1ac65ec5f9689f0d0c3ce61e67bad0b5fb36cfcd120b30519fc16218aba10c693</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26646759$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, J.C.-H.</creatorcontrib><creatorcontrib>Park, K.</creatorcontrib><creatorcontrib>Kim, J.-H.</creatorcontrib><creatorcontrib>Chen, Y.-M.</creatorcontrib><creatorcontrib>Chouaid, C.</creatorcontrib><creatorcontrib>Feng, J.-F.</creatorcontrib><creatorcontrib>Lu, S.</creatorcontrib><creatorcontrib>Vinnyk, Y.</creatorcontrib><creatorcontrib>Wiewrodt, R.</creatorcontrib><creatorcontrib>Zhou, C.</creatorcontrib><creatorcontrib>Wang, B.</creatorcontrib><creatorcontrib>Planchard, D.</creatorcontrib><creatorcontrib>Ignatius Ou, SaiHong</creatorcontrib><creatorcontrib>Planchard, David</creatorcontrib><creatorcontrib>Schuler, Martin</creatorcontrib><creatorcontrib>Chand, Vikram</creatorcontrib><creatorcontrib>Rohr, Klaus</creatorcontrib><creatorcontrib>Martin, Claudio Marcelo</creatorcontrib><creatorcontrib>Zarba, Juan Jose</creatorcontrib><creatorcontrib>Richardet, Martín</creatorcontrib><creatorcontrib>Mainwaring, Paul</creatorcontrib><creatorcontrib>Greil, Richard</creatorcontrib><creatorcontrib>Humblet, Yves</creatorcontrib><creatorcontrib>Bustin, Frédérique</creatorcontrib><creatorcontrib>Galdermans, Danny</creatorcontrib><creatorcontrib>Lambrechts, Marc</creatorcontrib><creatorcontrib>Vercauter, Piet</creatorcontrib><creatorcontrib>Wang, Jin</creatorcontrib><creatorcontrib>Huang, Cheng</creatorcontrib><creatorcontrib>Wu, Yilong</creatorcontrib><creatorcontrib>Cheng, Ying</creatorcontrib><creatorcontrib>Qin, Shukui</creatorcontrib><creatorcontrib>Zhang, Yiping</creatorcontrib><creatorcontrib>Lu, Shun</creatorcontrib><creatorcontrib>Garicochea, Bernardo</creatorcontrib><creatorcontrib>Alanko, Tuomo</creatorcontrib><creatorcontrib>Cadranel, Jacques</creatorcontrib><creatorcontrib>Chouaid, Christos</creatorcontrib><creatorcontrib>Zalcman, Gérard</creatorcontrib><creatorcontrib>Perol, Maurice</creatorcontrib><creatorcontrib>Fournel, Pierre</creatorcontrib><creatorcontrib>Gervais, Radj</creatorcontrib><creatorcontrib>Rotarski, Maciej</creatorcontrib><creatorcontrib>Thomas, Michael</creatorcontrib><creatorcontrib>Keilholz, Ulrich</creatorcontrib><creatorcontrib>Laack, Eckart</creatorcontrib><creatorcontrib>Strausz, Janos</creatorcontrib><creatorcontrib>Sarosi, Veronika</creatorcontrib><creatorcontrib>Jain, Minish</creatorcontrib><creatorcontrib>Venkatesan, Srinivasan</creatorcontrib><creatorcontrib>Sharma, Lalit</creatorcontrib><creatorcontrib>Dadhich, Hemant</creatorcontrib><creatorcontrib>Nagarkar, Rajnish Vasant</creatorcontrib><creatorcontrib>Gottfried, Maya</creatorcontrib><creatorcontrib>Stemmer, Solomon</creatorcontrib><creatorcontrib>Migliorino, Maria Rita</creatorcontrib><creatorcontrib>Grossi, Francesco</creatorcontrib><creatorcontrib>Gridelli, Cesare</creatorcontrib><creatorcontrib>Milandri, Carlo</creatorcontrib><creatorcontrib>Platania, Marco</creatorcontrib><creatorcontrib>Delgado, Francisco Gutierrez</creatorcontrib><creatorcontrib>Baca, Othon Padilla</creatorcontrib><creatorcontrib>Dingemans, A.M.C.</creatorcontrib><creatorcontrib>Herder, G.J.M.</creatorcontrib><creatorcontrib>Gans, S.J.M.</creatorcontrib><creatorcontrib>Salas Sánchez, Jorge Fernando</creatorcontrib><creatorcontrib>Pantigoso, Wilbert Rodriguez</creatorcontrib><creatorcontrib>Palomino, Osbert Luis Mejia</creatorcontrib><creatorcontrib>Kazarnowicz, Andrzej</creatorcontrib><creatorcontrib>Jassem, Jacek</creatorcontrib><creatorcontrib>Lubennikov, Vladimir</creatorcontrib><creatorcontrib>Karaseva, Nina</creatorcontrib><creatorcontrib>Ragulin, Yuri</creatorcontrib><creatorcontrib>Garrido, Pilar</creatorcontrib><creatorcontrib>González Larriba, José Luis</creatorcontrib><creatorcontrib>Camps, Carlos</creatorcontrib><creatorcontrib>Campelo, Rosario García</creatorcontrib><creatorcontrib>Cobo, Manuel</creatorcontrib><creatorcontrib>Felip, Enriqueta</creatorcontrib><creatorcontrib>Kim, Dong-Wan</creatorcontrib><creatorcontrib>Kim, Joo-Hang</creatorcontrib><creatorcontrib>Han, Ji-Youn</creatorcontrib><creatorcontrib>Kim, Young-Chul</creatorcontrib><creatorcontrib>Yang, Chih-Hsin</creatorcontrib><creatorcontrib>Hsia, Te-Chun</creatorcontrib><creatorcontrib>Tsai, Ying-Huang</creatorcontrib><creatorcontrib>Tsao, Thomas Chang-Yao</creatorcontrib><creatorcontrib>Ho, Ching-Liang</creatorcontrib><creatorcontrib>Vinnyk, Yuriy</creatorcontrib><creatorcontrib>Popovych, Oleksandr</creatorcontrib><creatorcontrib>Ponomarova, Olga</creatorcontrib><creatorcontrib>Bondarenko, Igor</creatorcontrib><creatorcontrib>Shah, Riyaz</creatorcontrib><creatorcontrib>Spicer, James</creatorcontrib><creatorcontrib>Brown, Emma</creatorcontrib><creatorcontrib>Upadhyay, Sunil</creatorcontrib><creatorcontrib>Summers, Yvonne</creatorcontrib><creatorcontrib>Gurtler, Jayne</creatorcontrib><creatorcontrib>Meza, Luis</creatorcontrib><creatorcontrib>Thropay, John</creatorcontrib><creatorcontrib>for the LUX-Lung 5 Investigators</creatorcontrib><creatorcontrib>LUX-Lung 5 Investigators</creatorcontrib><title>Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial</title><title>Annals of oncology</title><addtitle>Ann Oncol</addtitle><description>Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade with afatinib plus paclitaxel has superior outcomes versus switching to chemotherapy alone in patients acquiring resistance to erlotinib/gefitinib and afatinib monotherapy.
Patients with relapsed/refractory disease following ≥1 line of chemotherapy, and whose tumors had progressed following initial disease control (≥12 weeks) with erlotinib/gefitinib and thereafter afatinib (50 mg/day), were randomized 2:1 to receive afatinib plus paclitaxel (40 mg/day; 80 mg/m2/week) or investigator's choice of single-agent chemotherapy. The primary end point was progression-free survival (PFS). Other end points included objective response rate (ORR), overall survival (OS), safety and patient-reported outcomes.
Two hundred and two patients with progressive disease following clinical benefit from afatinib were randomized to afatinib plus paclitaxel (n = 134) or single-agent chemotherapy (n = 68). PFS (median 5.6 versus 2.8 months, hazard ratio 0.60, P = 0.003) and ORR (32.1% versus 13.2%, P = 0.005) significantly improved with afatinib plus paclitaxel. There was no difference in OS. Global health status/quality of life was maintained with afatinib plus paclitaxel over the entire treatment period. The median treatment duration was 133 and 51 days with afatinib plus paclitaxel and single-agent chemotherapy, respectively; 48.5% of patients receiving afatinib plus paclitaxel and 30.0% of patients receiving single-agent chemotherapy experienced drug-related grade 3/4 adverse events. Treatment-related adverse events were consistent with those previously reported with each agent.
Afatinib plus paclitaxel improved PFS and ORR compared with single-agent chemotherapy in patients who acquired resistance to erlotinib/gefitinib and progressed on afatinib after initial benefit. LUX-Lung 5 is the first prospective trial to demonstrate the benefit of continued ErbB targeting post-progression, versus switching to single-agent chemotherapy.
NCT01085136 (clinicaltrials.gov).</description><subject>Afatinib</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Disease Progression</subject><subject>Disease-Free Survival</subject><subject>ErbB Receptors - antagonists & inhibitors</subject><subject>ErbB Receptors - genetics</subject><subject>Erlotinib Hydrochloride - therapeutic use</subject><subject>Female</subject><subject>Gefitinib</subject><subject>Humans</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>NSCLC</subject><subject>Original</subject><subject>paclitaxel</subject><subject>Paclitaxel - adverse effects</subject><subject>Paclitaxel - therapeutic use</subject><subject>Prospective Studies</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Quinazolines - adverse effects</subject><subject>Quinazolines - therapeutic use</subject><subject>squamous cell</subject><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFu1DAURS0EosPAki3yBxDGTmJnzAKpqiiMNBIbKrGzHPt5YuTYkZ1ONf0hfrMeUipYsHrSu9f36Pki9JaSD5SIZqNCiEFvRnNkonuGVpRxUW1JS5-jFRF1U3WsaS_Qq5x_EkK4qMVLdFFz3vKOiRX6dWnV7ILrcQ-nGAyeUjwkyNnFgF3AU1EhzBnfuXnABVXlUXlfafAe-9twwFoFDQnb6H28c-fFAGOcB0hqOr3HkHz8DdgcwLoFpQpHPXI_4mlQGfBut8OpCHF092Dw_uZHtT_HMzwnp_xr9MIqn-HN41yjm-vP36--VvtvX3ZXl_tKtw2bK6o0Z6CZFXwrLDFENxo4Bd71ypCe2b7h2mpDa9I3hFFhNeU13apeUaK5aNbo05I73fYjGF1uT8rLKblRpZOMysl_leAGeYhH2XZciPLfa1QtATrFnBPYp7eUyHNjcmlMLo0V_7u_gU_uPxUVQ7cYoJx9dJBk1qUSDcYl0LM00f0n-gGOlK4b</recordid><startdate>20160301</startdate><enddate>20160301</enddate><creator>Yang, J.C.-H.</creator><creator>Park, K.</creator><creator>Kim, J.-H.</creator><creator>Chen, Y.-M.</creator><creator>Chouaid, C.</creator><creator>Feng, J.-F.</creator><creator>Lu, S.</creator><creator>Vinnyk, Y.</creator><creator>Wiewrodt, R.</creator><creator>Zhou, C.</creator><creator>Wang, B.</creator><creator>Planchard, D.</creator><creator>Ignatius Ou, SaiHong</creator><creator>Planchard, David</creator><creator>Schuler, Martin</creator><creator>Chand, Vikram</creator><creator>Rohr, Klaus</creator><creator>Martin, Claudio Marcelo</creator><creator>Zarba, Juan Jose</creator><creator>Richardet, Martín</creator><creator>Mainwaring, Paul</creator><creator>Greil, Richard</creator><creator>Humblet, Yves</creator><creator>Bustin, Frédérique</creator><creator>Galdermans, Danny</creator><creator>Lambrechts, Marc</creator><creator>Vercauter, Piet</creator><creator>Wang, Jin</creator><creator>Huang, Cheng</creator><creator>Wu, Yilong</creator><creator>Cheng, Ying</creator><creator>Qin, Shukui</creator><creator>Zhang, Yiping</creator><creator>Lu, Shun</creator><creator>Garicochea, Bernardo</creator><creator>Alanko, Tuomo</creator><creator>Cadranel, Jacques</creator><creator>Chouaid, Christos</creator><creator>Zalcman, Gérard</creator><creator>Perol, Maurice</creator><creator>Fournel, Pierre</creator><creator>Gervais, Radj</creator><creator>Rotarski, Maciej</creator><creator>Thomas, Michael</creator><creator>Keilholz, Ulrich</creator><creator>Laack, Eckart</creator><creator>Strausz, Janos</creator><creator>Sarosi, Veronika</creator><creator>Jain, Minish</creator><creator>Venkatesan, Srinivasan</creator><creator>Sharma, Lalit</creator><creator>Dadhich, Hemant</creator><creator>Nagarkar, Rajnish Vasant</creator><creator>Gottfried, Maya</creator><creator>Stemmer, Solomon</creator><creator>Migliorino, Maria Rita</creator><creator>Grossi, Francesco</creator><creator>Gridelli, Cesare</creator><creator>Milandri, Carlo</creator><creator>Platania, Marco</creator><creator>Delgado, Francisco Gutierrez</creator><creator>Baca, Othon Padilla</creator><creator>Dingemans, A.M.C.</creator><creator>Herder, G.J.M.</creator><creator>Gans, S.J.M.</creator><creator>Salas Sánchez, Jorge Fernando</creator><creator>Pantigoso, Wilbert Rodriguez</creator><creator>Palomino, Osbert Luis Mejia</creator><creator>Kazarnowicz, Andrzej</creator><creator>Jassem, Jacek</creator><creator>Lubennikov, Vladimir</creator><creator>Karaseva, Nina</creator><creator>Ragulin, Yuri</creator><creator>Garrido, Pilar</creator><creator>González Larriba, José Luis</creator><creator>Camps, Carlos</creator><creator>Campelo, Rosario García</creator><creator>Cobo, Manuel</creator><creator>Felip, Enriqueta</creator><creator>Kim, Dong-Wan</creator><creator>Kim, Joo-Hang</creator><creator>Han, Ji-Youn</creator><creator>Kim, Young-Chul</creator><creator>Yang, Chih-Hsin</creator><creator>Hsia, Te-Chun</creator><creator>Tsai, Ying-Huang</creator><creator>Tsao, Thomas Chang-Yao</creator><creator>Ho, Ching-Liang</creator><creator>Vinnyk, Yuriy</creator><creator>Popovych, Oleksandr</creator><creator>Ponomarova, Olga</creator><creator>Bondarenko, Igor</creator><creator>Shah, Riyaz</creator><creator>Spicer, James</creator><creator>Brown, Emma</creator><creator>Upadhyay, Sunil</creator><creator>Summers, Yvonne</creator><creator>Gurtler, Jayne</creator><creator>Meza, Luis</creator><creator>Thropay, John</creator><general>Elsevier Ltd</general><general>Oxford University Press</general><scope>6I.</scope><scope>AAFTH</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20160301</creationdate><title>Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial</title><author>Yang, J.C.-H. ; Park, K. ; Kim, J.-H. ; Chen, Y.-M. ; Chouaid, C. ; Feng, J.-F. ; Lu, S. ; Vinnyk, Y. ; Wiewrodt, R. ; Zhou, C. ; Wang, B. ; Planchard, D. ; Ignatius Ou, SaiHong ; Planchard, David ; Schuler, Martin ; Chand, Vikram ; Rohr, Klaus ; Martin, Claudio Marcelo ; Zarba, Juan Jose ; Richardet, Martín ; Mainwaring, Paul ; Greil, Richard ; Humblet, Yves ; Bustin, Frédérique ; Galdermans, Danny ; Lambrechts, Marc ; Vercauter, Piet ; Wang, Jin ; Huang, Cheng ; Wu, Yilong ; Cheng, Ying ; Qin, Shukui ; Zhang, Yiping ; Lu, Shun ; Garicochea, Bernardo ; Alanko, Tuomo ; Cadranel, Jacques ; Chouaid, Christos ; Zalcman, Gérard ; Perol, Maurice ; Fournel, Pierre ; Gervais, Radj ; Rotarski, Maciej ; Thomas, Michael ; Keilholz, Ulrich ; Laack, Eckart ; Strausz, Janos ; Sarosi, Veronika ; Jain, Minish ; Venkatesan, Srinivasan ; Sharma, Lalit ; Dadhich, Hemant ; Nagarkar, Rajnish Vasant ; Gottfried, Maya ; Stemmer, Solomon ; Migliorino, Maria Rita ; Grossi, Francesco ; Gridelli, Cesare ; Milandri, Carlo ; Platania, Marco ; Delgado, Francisco Gutierrez ; Baca, Othon Padilla ; Dingemans, A.M.C. ; Herder, G.J.M. ; Gans, S.J.M. ; Salas Sánchez, Jorge Fernando ; Pantigoso, Wilbert Rodriguez ; Palomino, Osbert Luis Mejia ; Kazarnowicz, Andrzej ; Jassem, Jacek ; Lubennikov, Vladimir ; Karaseva, Nina ; Ragulin, Yuri ; Garrido, Pilar ; González Larriba, José Luis ; Camps, Carlos ; Campelo, Rosario García ; Cobo, Manuel ; Felip, Enriqueta ; Kim, Dong-Wan ; Kim, Joo-Hang ; Han, Ji-Youn ; Kim, Young-Chul ; Yang, Chih-Hsin ; Hsia, Te-Chun ; Tsai, Ying-Huang ; Tsao, Thomas Chang-Yao ; Ho, Ching-Liang ; Vinnyk, Yuriy ; Popovych, Oleksandr ; Ponomarova, Olga ; Bondarenko, Igor ; Shah, Riyaz ; Spicer, James ; Brown, Emma ; Upadhyay, Sunil ; Summers, Yvonne ; Gurtler, Jayne ; Meza, Luis ; Thropay, John</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c435t-1ac65ec5f9689f0d0c3ce61e67bad0b5fb36cfcd120b30519fc16218aba10c693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Afatinib</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Disease Progression</topic><topic>Disease-Free Survival</topic><topic>ErbB Receptors - antagonists & inhibitors</topic><topic>ErbB Receptors - genetics</topic><topic>Erlotinib Hydrochloride - therapeutic use</topic><topic>Female</topic><topic>Gefitinib</topic><topic>Humans</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>NSCLC</topic><topic>Original</topic><topic>paclitaxel</topic><topic>Paclitaxel - adverse effects</topic><topic>Paclitaxel - therapeutic use</topic><topic>Prospective Studies</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Quinazolines - adverse effects</topic><topic>Quinazolines - therapeutic use</topic><topic>squamous cell</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, J.C.-H.</creatorcontrib><creatorcontrib>Park, K.</creatorcontrib><creatorcontrib>Kim, J.-H.</creatorcontrib><creatorcontrib>Chen, Y.-M.</creatorcontrib><creatorcontrib>Chouaid, C.</creatorcontrib><creatorcontrib>Feng, J.-F.</creatorcontrib><creatorcontrib>Lu, S.</creatorcontrib><creatorcontrib>Vinnyk, Y.</creatorcontrib><creatorcontrib>Wiewrodt, R.</creatorcontrib><creatorcontrib>Zhou, C.</creatorcontrib><creatorcontrib>Wang, B.</creatorcontrib><creatorcontrib>Planchard, D.</creatorcontrib><creatorcontrib>Ignatius Ou, SaiHong</creatorcontrib><creatorcontrib>Planchard, David</creatorcontrib><creatorcontrib>Schuler, Martin</creatorcontrib><creatorcontrib>Chand, Vikram</creatorcontrib><creatorcontrib>Rohr, Klaus</creatorcontrib><creatorcontrib>Martin, Claudio Marcelo</creatorcontrib><creatorcontrib>Zarba, Juan Jose</creatorcontrib><creatorcontrib>Richardet, Martín</creatorcontrib><creatorcontrib>Mainwaring, Paul</creatorcontrib><creatorcontrib>Greil, Richard</creatorcontrib><creatorcontrib>Humblet, Yves</creatorcontrib><creatorcontrib>Bustin, Frédérique</creatorcontrib><creatorcontrib>Galdermans, Danny</creatorcontrib><creatorcontrib>Lambrechts, Marc</creatorcontrib><creatorcontrib>Vercauter, Piet</creatorcontrib><creatorcontrib>Wang, Jin</creatorcontrib><creatorcontrib>Huang, Cheng</creatorcontrib><creatorcontrib>Wu, Yilong</creatorcontrib><creatorcontrib>Cheng, Ying</creatorcontrib><creatorcontrib>Qin, Shukui</creatorcontrib><creatorcontrib>Zhang, Yiping</creatorcontrib><creatorcontrib>Lu, Shun</creatorcontrib><creatorcontrib>Garicochea, Bernardo</creatorcontrib><creatorcontrib>Alanko, Tuomo</creatorcontrib><creatorcontrib>Cadranel, Jacques</creatorcontrib><creatorcontrib>Chouaid, Christos</creatorcontrib><creatorcontrib>Zalcman, Gérard</creatorcontrib><creatorcontrib>Perol, Maurice</creatorcontrib><creatorcontrib>Fournel, Pierre</creatorcontrib><creatorcontrib>Gervais, Radj</creatorcontrib><creatorcontrib>Rotarski, Maciej</creatorcontrib><creatorcontrib>Thomas, Michael</creatorcontrib><creatorcontrib>Keilholz, Ulrich</creatorcontrib><creatorcontrib>Laack, Eckart</creatorcontrib><creatorcontrib>Strausz, Janos</creatorcontrib><creatorcontrib>Sarosi, Veronika</creatorcontrib><creatorcontrib>Jain, Minish</creatorcontrib><creatorcontrib>Venkatesan, Srinivasan</creatorcontrib><creatorcontrib>Sharma, Lalit</creatorcontrib><creatorcontrib>Dadhich, Hemant</creatorcontrib><creatorcontrib>Nagarkar, Rajnish Vasant</creatorcontrib><creatorcontrib>Gottfried, Maya</creatorcontrib><creatorcontrib>Stemmer, Solomon</creatorcontrib><creatorcontrib>Migliorino, Maria Rita</creatorcontrib><creatorcontrib>Grossi, Francesco</creatorcontrib><creatorcontrib>Gridelli, Cesare</creatorcontrib><creatorcontrib>Milandri, Carlo</creatorcontrib><creatorcontrib>Platania, Marco</creatorcontrib><creatorcontrib>Delgado, Francisco Gutierrez</creatorcontrib><creatorcontrib>Baca, Othon Padilla</creatorcontrib><creatorcontrib>Dingemans, A.M.C.</creatorcontrib><creatorcontrib>Herder, G.J.M.</creatorcontrib><creatorcontrib>Gans, S.J.M.</creatorcontrib><creatorcontrib>Salas Sánchez, Jorge Fernando</creatorcontrib><creatorcontrib>Pantigoso, Wilbert Rodriguez</creatorcontrib><creatorcontrib>Palomino, Osbert Luis Mejia</creatorcontrib><creatorcontrib>Kazarnowicz, Andrzej</creatorcontrib><creatorcontrib>Jassem, Jacek</creatorcontrib><creatorcontrib>Lubennikov, Vladimir</creatorcontrib><creatorcontrib>Karaseva, Nina</creatorcontrib><creatorcontrib>Ragulin, Yuri</creatorcontrib><creatorcontrib>Garrido, Pilar</creatorcontrib><creatorcontrib>González Larriba, José Luis</creatorcontrib><creatorcontrib>Camps, Carlos</creatorcontrib><creatorcontrib>Campelo, Rosario García</creatorcontrib><creatorcontrib>Cobo, Manuel</creatorcontrib><creatorcontrib>Felip, Enriqueta</creatorcontrib><creatorcontrib>Kim, Dong-Wan</creatorcontrib><creatorcontrib>Kim, Joo-Hang</creatorcontrib><creatorcontrib>Han, Ji-Youn</creatorcontrib><creatorcontrib>Kim, Young-Chul</creatorcontrib><creatorcontrib>Yang, Chih-Hsin</creatorcontrib><creatorcontrib>Hsia, Te-Chun</creatorcontrib><creatorcontrib>Tsai, Ying-Huang</creatorcontrib><creatorcontrib>Tsao, Thomas Chang-Yao</creatorcontrib><creatorcontrib>Ho, Ching-Liang</creatorcontrib><creatorcontrib>Vinnyk, Yuriy</creatorcontrib><creatorcontrib>Popovych, Oleksandr</creatorcontrib><creatorcontrib>Ponomarova, Olga</creatorcontrib><creatorcontrib>Bondarenko, Igor</creatorcontrib><creatorcontrib>Shah, Riyaz</creatorcontrib><creatorcontrib>Spicer, James</creatorcontrib><creatorcontrib>Brown, Emma</creatorcontrib><creatorcontrib>Upadhyay, Sunil</creatorcontrib><creatorcontrib>Summers, Yvonne</creatorcontrib><creatorcontrib>Gurtler, Jayne</creatorcontrib><creatorcontrib>Meza, Luis</creatorcontrib><creatorcontrib>Thropay, John</creatorcontrib><creatorcontrib>for the LUX-Lung 5 Investigators</creatorcontrib><creatorcontrib>LUX-Lung 5 Investigators</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, J.C.-H.</au><au>Park, K.</au><au>Kim, J.-H.</au><au>Chen, Y.-M.</au><au>Chouaid, C.</au><au>Feng, J.-F.</au><au>Lu, S.</au><au>Vinnyk, Y.</au><au>Wiewrodt, R.</au><au>Zhou, C.</au><au>Wang, B.</au><au>Planchard, D.</au><au>Ignatius Ou, SaiHong</au><au>Planchard, David</au><au>Schuler, Martin</au><au>Chand, Vikram</au><au>Rohr, Klaus</au><au>Martin, Claudio Marcelo</au><au>Zarba, Juan Jose</au><au>Richardet, Martín</au><au>Mainwaring, Paul</au><au>Greil, Richard</au><au>Humblet, Yves</au><au>Bustin, Frédérique</au><au>Galdermans, Danny</au><au>Lambrechts, Marc</au><au>Vercauter, Piet</au><au>Wang, Jin</au><au>Huang, Cheng</au><au>Wu, Yilong</au><au>Cheng, Ying</au><au>Qin, Shukui</au><au>Zhang, Yiping</au><au>Lu, Shun</au><au>Garicochea, Bernardo</au><au>Alanko, Tuomo</au><au>Cadranel, Jacques</au><au>Chouaid, Christos</au><au>Zalcman, Gérard</au><au>Perol, Maurice</au><au>Fournel, Pierre</au><au>Gervais, Radj</au><au>Rotarski, Maciej</au><au>Thomas, Michael</au><au>Keilholz, Ulrich</au><au>Laack, Eckart</au><au>Strausz, Janos</au><au>Sarosi, Veronika</au><au>Jain, Minish</au><au>Venkatesan, Srinivasan</au><au>Sharma, Lalit</au><au>Dadhich, Hemant</au><au>Nagarkar, Rajnish Vasant</au><au>Gottfried, Maya</au><au>Stemmer, Solomon</au><au>Migliorino, Maria Rita</au><au>Grossi, Francesco</au><au>Gridelli, Cesare</au><au>Milandri, Carlo</au><au>Platania, Marco</au><au>Delgado, Francisco Gutierrez</au><au>Baca, Othon Padilla</au><au>Dingemans, A.M.C.</au><au>Herder, G.J.M.</au><au>Gans, S.J.M.</au><au>Salas Sánchez, Jorge Fernando</au><au>Pantigoso, Wilbert Rodriguez</au><au>Palomino, Osbert Luis Mejia</au><au>Kazarnowicz, Andrzej</au><au>Jassem, Jacek</au><au>Lubennikov, Vladimir</au><au>Karaseva, Nina</au><au>Ragulin, Yuri</au><au>Garrido, Pilar</au><au>González Larriba, José Luis</au><au>Camps, Carlos</au><au>Campelo, Rosario García</au><au>Cobo, Manuel</au><au>Felip, Enriqueta</au><au>Kim, Dong-Wan</au><au>Kim, Joo-Hang</au><au>Han, Ji-Youn</au><au>Kim, Young-Chul</au><au>Yang, Chih-Hsin</au><au>Hsia, Te-Chun</au><au>Tsai, Ying-Huang</au><au>Tsao, Thomas Chang-Yao</au><au>Ho, Ching-Liang</au><au>Vinnyk, Yuriy</au><au>Popovych, Oleksandr</au><au>Ponomarova, Olga</au><au>Bondarenko, Igor</au><au>Shah, Riyaz</au><au>Spicer, James</au><au>Brown, Emma</au><au>Upadhyay, Sunil</au><au>Summers, Yvonne</au><au>Gurtler, Jayne</au><au>Meza, Luis</au><au>Thropay, John</au><aucorp>for the LUX-Lung 5 Investigators</aucorp><aucorp>LUX-Lung 5 Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial</atitle><jtitle>Annals of oncology</jtitle><addtitle>Ann Oncol</addtitle><date>2016-03-01</date><risdate>2016</risdate><volume>27</volume><issue>3</issue><spage>417</spage><epage>423</epage><pages>417-423</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Afatinib has demonstrated clinical benefit in patients with non-small-cell lung cancer progressing after treatment with erlotinib/gefitinib. This phase III trial prospectively assessed whether continued irreversible ErbB-family blockade with afatinib plus paclitaxel has superior outcomes versus switching to chemotherapy alone in patients acquiring resistance to erlotinib/gefitinib and afatinib monotherapy.
Patients with relapsed/refractory disease following ≥1 line of chemotherapy, and whose tumors had progressed following initial disease control (≥12 weeks) with erlotinib/gefitinib and thereafter afatinib (50 mg/day), were randomized 2:1 to receive afatinib plus paclitaxel (40 mg/day; 80 mg/m2/week) or investigator's choice of single-agent chemotherapy. The primary end point was progression-free survival (PFS). Other end points included objective response rate (ORR), overall survival (OS), safety and patient-reported outcomes.
Two hundred and two patients with progressive disease following clinical benefit from afatinib were randomized to afatinib plus paclitaxel (n = 134) or single-agent chemotherapy (n = 68). PFS (median 5.6 versus 2.8 months, hazard ratio 0.60, P = 0.003) and ORR (32.1% versus 13.2%, P = 0.005) significantly improved with afatinib plus paclitaxel. There was no difference in OS. Global health status/quality of life was maintained with afatinib plus paclitaxel over the entire treatment period. The median treatment duration was 133 and 51 days with afatinib plus paclitaxel and single-agent chemotherapy, respectively; 48.5% of patients receiving afatinib plus paclitaxel and 30.0% of patients receiving single-agent chemotherapy experienced drug-related grade 3/4 adverse events. Treatment-related adverse events were consistent with those previously reported with each agent.
Afatinib plus paclitaxel improved PFS and ORR compared with single-agent chemotherapy in patients who acquired resistance to erlotinib/gefitinib and progressed on afatinib after initial benefit. LUX-Lung 5 is the first prospective trial to demonstrate the benefit of continued ErbB targeting post-progression, versus switching to single-agent chemotherapy.
NCT01085136 (clinicaltrials.gov).</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>26646759</pmid><doi>10.1093/annonc/mdv597</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2016-03, Vol.27 (3), p.417-423 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4769992 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Afatinib Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Disease Progression Disease-Free Survival ErbB Receptors - antagonists & inhibitors ErbB Receptors - genetics Erlotinib Hydrochloride - therapeutic use Female Gefitinib Humans Lung Neoplasms - drug therapy Male Middle Aged NSCLC Original paclitaxel Paclitaxel - adverse effects Paclitaxel - therapeutic use Prospective Studies Protein Kinase Inhibitors - therapeutic use Quinazolines - adverse effects Quinazolines - therapeutic use squamous cell |
| title | Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T01%3A16%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Afatinib%20beyond%20progression%20in%20patients%20with%20non-small-cell%20lung%20cancer%20following%20chemotherapy,%20erlotinib/gefitinib%20and%20afatinib:%20phase%20III%20randomized%20LUX-Lung%205%20trial&rft.jtitle=Annals%20of%20oncology&rft.au=Yang,%20J.C.-H.&rft.aucorp=for%20the%20LUX-Lung%205%20Investigators&rft.date=2016-03-01&rft.volume=27&rft.issue=3&rft.spage=417&rft.epage=423&rft.pages=417-423&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdv597&rft_dat=%3Celsevier_pubme%3ES0923753419355942%3C/elsevier_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/26646759&rft_els_id=S0923753419355942&rfr_iscdi=true |